Suchergebnisse - "Voest, Emile E"

PubPharm (381)

1

Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics

enthalten in: bioRxiv.org | 2024

von Koster, R. | Schipper, L. | Giesbertz, N. | +16

2

Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load : results from the Drug Rediscovery Protocol

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Geurts, B. | Zeverijn, L. | Leek, L. | +18

3

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer : Results from the drug rediscovery protocol (DRUP)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Spiekman, I. | Zeverijn, L. | Geurts, B. | +15

4

Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells

enthalten in: Cancer discovery | 2024

von Picco, G. | Rao, Y. | Al Saedi, A. | +44

5

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von van de Haar, J. | Mankor, J. | Hummelink, K. | +6

6

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

enthalten in: Nature protocols | 2024

von Samsom, K. | Bosch, L. | Schipper, L. | +26

7

Author Correction : Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

enthalten in: Nature medicine | 2024

von Verschoor, Y. | van de Haar, J. | van den Berg, J. | +21

ErratumFor: Nat Med. 2024 Feb;30(2):519-530. - PMID 38191613

8

Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics

enthalten in: Genetics in medicine : official journal of the American College of Medical Genetics | 2024

von Koster, R. | Schipper, L. | Giesbertz, N. | +16

9

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma : the phase 2 PANDA trial

enthalten in: Nature medicine | 2024

von Verschoor, Y. | van de Haar, J. | van den Berg, J. | +21

ErratumIn: Nat Med. 2024 Mar 6;:. - PMID 38448792

10

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma : Results From the Drug Rediscovery Protocol

enthalten in: The oncologist | 2023

von Spiekman, I. | Geurts, B. | Zeverijn, L. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]